Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo controlled Phase II study is designed to assess the safety and efficacy of using JVS-100 to treat heart failure.

Clinical Trial Description

90 subjects with ischemic cardiomyopathy will be randomized to receive a single dose of 15 or 30 mg of JVS-100 or matching placebo. Subjects will be randomized 1:1:1 to receive either placebo, 15 mg or 30 mg of JVS-100. Subjects will be monitored overnight for 18-24 hours post dose and have scheduled visits at 3 days post-injection for safety evaluations. All subjects will be scheduled for follow-up visits at approximately 30 days (1 month), 120 days (4 months), and 360 days (12 months) to assess safety and cardiac function. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT01643590
Study type Interventional
Source Juventas Therapeutics, Inc.
Status Active, not recruiting
Phase Phase 2
Start date July 2012
Completion date November 2014

See also
  Status Clinical Trial Phase
Terminated NCT02240940 - PARACHUTE China Approval Trial N/A
Completed NCT00846001 - Resynchronization Surgery Combined Unified Efficacy Phase 3
Active, not recruiting NCT01961726 - Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure Phase 1/Phase 2
Terminated NCT00102128 - Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack. Phase 2
Not yet recruiting NCT03491969 - Clinical Study of Lipoic Acid on Ischemic Heart Failure Phase 4
Recruiting NCT01555320 - Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure N/A
Recruiting NCT02875639 - A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome) Phase 2
Active, not recruiting NCT02700880 - LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry N/A
Active, not recruiting NCT02115568 - Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203 N/A
Recruiting NCT03206593 - Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure N/A
Enrolling by invitation NCT01709279 - Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure N/A